Khaled Sanber

846 total citations
11 papers, 248 citations indexed

About

Khaled Sanber is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Khaled Sanber has authored 11 papers receiving a total of 248 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Genetics. Recurrent topics in Khaled Sanber's work include CAR-T cell therapy research (5 papers), Virus-based gene therapy research (3 papers) and Viral Infectious Diseases and Gene Expression in Insects (2 papers). Khaled Sanber is often cited by papers focused on CAR-T cell therapy research (5 papers), Virus-based gene therapy research (3 papers) and Viral Infectious Diseases and Gene Expression in Insects (2 papers). Khaled Sanber collaborates with scholars based in United States, United Kingdom and Japan. Khaled Sanber's co-authors include Tania Jain, Bipin N. Savani, Mary Collins, Yasuhiro Takeuchi, David Escors, Giorgia Santilli, Ahmed Z. Gad, Gi‐Ja Lee, R.A. Youness and Jeremy Minshull and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and British Journal of Haematology.

In The Last Decade

Khaled Sanber

9 papers receiving 241 citations

Peers

Khaled Sanber

MB

ONCOL

GENET

IMMUN

BIOCH

Lie Ma China

Marcos Vásquez Spain

Rajat K. Das India

Qi Deng China

Chenqiang Jia China

Eloise Scamardella Italy

JH Wang China

Shuangshuang Lu China

Cristiana Zanetti Italy

Ting Fu United States

Lie Ma China

Khaled Sanber

235 ×1.8

MB

85 ×0.7

ONCOL

93 ×1.0

GENET

23 ×0.5

IMMUN

4 ×0.1

BIOCH

Citations per year, relative to Khaled Sanber Khaled Sanber (= 1×) peers Lie Ma

Countries citing papers authored by Khaled Sanber

Since Specialization

Citations

This map shows the geographic impact of Khaled Sanber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Khaled Sanber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Khaled Sanber more than expected).

Fields of papers citing papers by Khaled Sanber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Khaled Sanber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Khaled Sanber. The network helps show where Khaled Sanber may publish in the future.

Co-authorship network of co-authors of Khaled Sanber

This figure shows the co-authorship network connecting the top 25 collaborators of Khaled Sanber. A scholar is included among the top collaborators of Khaled Sanber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Khaled Sanber. Khaled Sanber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Sanber, Khaled, Samuel Rosner, Patrick M. Forde, & Kristen A. Marrone. (2023). Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer. BioDrugs. 37(6). 775–791. 4 indexed citations

2.

Sanber, Khaled, Hua‐Ling Tsai, Jonathan Webster, et al.. (2023). Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease. Leukemia & lymphoma. 64(4). 846–855. 3 indexed citations

3.

Choe, Michelle, Matthew Campbell, Khaled Sanber, et al.. (2023). Engaging c-MET (mesenchymal-epithelial transition factor) Axis to Enhance the Safety and Antitumor Function of HER2-CAR T-Cells in Sarcoma. Transplantation and Cellular Therapy. 29(2). S224–S224. 1 indexed citations

4.

Sanber, Khaled, Bipin N. Savani, & Tania Jain. (2021). Graft‐versus‐host disease risk after chimeric antigen receptor T‐cell therapy: the diametric opposition of T cells. British Journal of Haematology. 195(5). 660–668. 72 indexed citations

5.

Youness, R.A., Ahmed Z. Gad, Khaled Sanber, et al.. (2020). Targeting hydrogen sulphide signaling in breast cancer. Journal of Advanced Research. 27. 177–190. 75 indexed citations

6.

Sanber, Khaled, Vita S. Salsman, Ahmed Z. Gad, et al.. (2020). Modulation of inhibitory signals in CAR T cells leads to improved activity against glioblastoma.. Journal of Clinical Oncology. 38(15_suppl). 3031–3031.

7.

Sanber, Khaled, et al.. (2020). I-PASS Illness Severity Identifies Patients at Risk for Overnight Clinical Deterioration. Journal of Graduate Medical Education. 12(5). 578–582. 3 indexed citations

8.

Sanber, Khaled, Vita S. Salsman, Ahmed Z. Gad, et al.. (2020). Modulation of inhibitory receptor signaling pathways improves CAR T cell activity against glioblastoma. Cytotherapy. 22(5). S19–S20.

9.

Munis, Altar M., Christopher Perry, Khaled Sanber, et al.. (2018). Lentivector Producer Cell Lines with Stably Expressed Vesiculovirus Envelopes. Molecular Therapy — Methods & Clinical Development. 10. 303–312. 12 indexed citations

10.

Sanber, Khaled, Sean Knight, Sam L. Stephen, et al.. (2015). Construction of stable packaging cell lines for clinical lentiviral vector production. Scientific Reports. 5(1). 9021–9021. 76 indexed citations

11.

Badran, Yousef R., et al.. (2015). Effect of Interleukins on Antibody Production by Epstein-Barr Virus Transformed B Cells. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 34(3). 162–168. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact